Horizon Adaptive Platform

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
300 patients (estimated)
Sponsors
Multiple Myeloma Research Consortium
Tags
B-Cell Maturation Antigen (BCMA), CD3, Closed Label (Masked), Randomization
Trial Type
Treatment
Last Update
1 week ago
SparkCures ID
1876
NCT Identifier
NCT06171685

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.